The Estée Lauder Companies Inc. (ELC) is collaborating with Serpin Pharma to explore how Serpin’s anti-inflammatory research can be applied in cosmetics.

The partnership accelerates ELC’s focus on transformative innovation by applying insights from Serpin Pharma’s two decades of anti-inflammatory research. Serpin’s biotech technology mitigates inflammation and enhances cell resiliency. Serpin identified proteins called SERPINs (Serine Protease Inhibitors) that enhance the body’s natural ability to heal cells experiencing inflammation. The companies are harnessing the technology to address skin irritation, aging and sensitivity. Scientific studies are underway to demonstrate how Serpin’s technology can be applied to cosmetics to rapidly and visibly reduce skin aging and irritation.

“This novel technology will advance our transformative innovation agenda by pushing the boundaries of breakthrough scientific discovery,” said Carl Haney, EVP-global innovation and research and development (R&D), ELC.

Biotech Ingredients Mitigate Skin Irritation and Sensitivity

The partnership explores powerful new biological pathways and cutting-edge biotech ingredients to rapidly mitigate visible skin irritation and sensitivity for ELC’s prestige beauty consumers, he added.

“Serpin Pharma was founded on the principles of biomimicry and how nature solves for signs of trauma and injury,” said Cohava Gelber, PhD, MBA, founder, executive chairperson and CEO, Serpin Pharma. “We’re taking a novel approach by tapping into the body’s innate mechanism for resolving inflammation. We are proud to partner with ELC to explore how our powerful biotechnology can be applied to cosmetics and skincare.”

This work builds on ELC’s decades-long leadership in longevity science, biotechnology and fermentation. ELC partners with biotech companies across sectors to commercialize their breakthrough innovations and apply their technologies to develop skincare solutions. It also reinforces ELC’s commitment to creating transformative product innovation to deliver fast-to-market, on-trend innovation across in-demand subcategories, benefits and occasions, as part of ELC’s new Beauty Reimagined strategic vision.

Serpin’s Peptide Pipeline Treats Inflammation

Serpin Pharma is a clinical-stage pharmaceutical company. It develops anti-inflammatory and immune-modulating therapies to treat diseases driven by inflammation. Located in Manassas, Virginia, Serpin engineered a small, highly selective peptide therapeutic that is 300 times greater than that of its natural counterpart, Alfa-1 Antitrypsin (A1AT), in delivering anti-inflammatory and regenerative effects.

Serpin’s drug platform halts unchecked inflammation without compromising the immune system. It also promotes the repair and regeneration of cells and tissues affected by inflammation, injury or trauma. The company has 13 robust patents securing its pipeline technologies.